FAAH-IN-10
FAAH-IN-10 is a FAAH inhibitor and TRPV1 antagonist, with an IC50 of 0.57 μM against human FAAH. FAAH-IN-10 regulates FAAH activity, antagonizes TRPV1 activity, and exhibits analgesic and anti-inflammatory activities. FAAH-IN-10 does not induce TRPV1-mediated hyperthermia. FAAH-IN-10 can be used for pain-related research.
For research use only. We do not sell to patients.
- Formula: C24H25N3O3S
- Molecular Weight:435.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
TRPV1 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming mice (male, 22-35 g)[1]
-
Dosage:10 mg/kg; 20 mg/kg; 30 mg/kg; 40 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly reduced licking/biting time in both phase I and phase II at 30 mg/kg, with greater efficacy than positive control AA-5-HT.
Reduced phase II licking/biting time in a dose-dependent manner at 10, 20, and 40 mg/kg.
Significantly reduced phase I licking/biting time compared to vehicle at 40 mg/kg.
-
Animal Model:unstated strain[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.p.; single dose
-
Result:Exhibited superior anti-edema effects relative to AA-5-HT (5 mg/kg) at 5, 10, and 20 mg/kg.
Showed a clear dose-response relationship, with escalating doses producing progressively greater inhibition of paw edema.
-
Animal Model:unstated strain[1]
-
Dosage:5 mg/kg; graded unspecified doses
-
Administration:i.p.; single dose
-
Result:Did not produce a statistically significant increase in core body temperature at any time point up to 180 minutes post-injection, unlike BCTC.
Showed no significant differences in rectal temperature between compound 31-treated groups and vehicle group at all assessed time points in follow-up dose-ranging study.
-
Animal Model:Kunming mice (male, 22-35 g)[1]
-
Dosage:10 mg/kg; 20 mg/kg; 40 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly reduced licking duration in a dose-dependent manner, with greater reductions observed at higher doses.
-
Animal Model:Kunming mice (male, 22-35 g)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly shortened formalin-induced phase II licking/biting time compared to vehicle.
Had its analgesic effect reversed by pretreatment with AM251, which significantly prolonged licking/biting duration.
Chemical Information
-
Molecular Weight 435.54
-
Formula C24H25N3O3S
-
SMILES
O=C(OC1=CC=CC=C1)NCCCC(N2[C@H](C3=NC(C4=CC=CC=C4)=CS3)CCC2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FAAH-IN-10 Related Classifications
HY-184331 Related Classifications
Powered by Bioz
Keywords
- FAAH-IN-10
- FAAH
- TRP Channel
- carrageenan-induced paw edema model
- human TRPV1-transfected HEK-293 cells
- mice
- CB receptor
- capsaicin-induced pain model
- human recombinant FAAH enzyme
- human FAAH
- formalin-induced pain model
- transient receptor potential vanilloid type 1
- fatty acid amide hydrolase
- Inhibitor
- inhibitor
- inhibit